An oral B subunit: whole cell vaccine against cholera

J. Holmgren, A. M. Svennerholm, M. Jertborn, J. Clemens, D. A. Sack, R. Salenstedt, H. Wigzell

Research output: Contribution to journalArticle

Abstract

During the last decade there has been a rapid progress in the development of new, much improved vaccines against cholera. These vaccines, which are given orally to stimulate the gut mucosal immune system, are based on either a combination of purified cholera toxin B (binding) subunit and killed cholera vibrios of Inaba and Ogawa serotypes and El Tor and classical biotypes (B subunit-whole cell vaccine, B-WC) or on a live attenuated mutant strain of Vibrio cholerae producing the B subunit (CVD 103-HgR). The safety of the oral B-WC cholera vaccine and the immunogenicity and protective efficacy of this vaccine against both cholera and diarrhoea caused by enterotoxigenic Escherichia coli have been extensively documented, e.g. in a large randomized, placebo-controlled field trial in 90 000 persons living in a cholera endemic area. The potential for inexpensive large-scale manufacturing of the B-WC vaccine has recently been much facilitated by the introduction of recombinant DNA technology for production of the B subunit component. This now gives promise that this vaccine could become a useful, cost-effective tool in future strategies to control cholera both in endemic situations and in relation to acute epidemic outbreaks.

Original languageEnglish (US)
Pages (from-to)911-914
Number of pages4
JournalVaccine
Volume10
Issue number13
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Cholera Vaccines
cholera
mouth
Vaccines
vaccines
Cholera
cells
Vibrio cholerae
Enterotoxigenic Escherichia coli
Recombinant DNA
Cholera Toxin
enterotoxigenic Escherichia coli
recombinant DNA
cholera toxin
Disease Outbreaks
Diarrhea
Immune System
biotypes
Placebos
placebos

Keywords

  • B subunit-whole cell vaccine
  • Cholera
  • field trials
  • oral

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Holmgren, J., Svennerholm, A. M., Jertborn, M., Clemens, J., Sack, D. A., Salenstedt, R., & Wigzell, H. (1992). An oral B subunit: whole cell vaccine against cholera. Vaccine, 10(13), 911-914. https://doi.org/10.1016/0264-410X(92)90324-D

An oral B subunit : whole cell vaccine against cholera. / Holmgren, J.; Svennerholm, A. M.; Jertborn, M.; Clemens, J.; Sack, D. A.; Salenstedt, R.; Wigzell, H.

In: Vaccine, Vol. 10, No. 13, 1992, p. 911-914.

Research output: Contribution to journalArticle

Holmgren, J, Svennerholm, AM, Jertborn, M, Clemens, J, Sack, DA, Salenstedt, R & Wigzell, H 1992, 'An oral B subunit: whole cell vaccine against cholera', Vaccine, vol. 10, no. 13, pp. 911-914. https://doi.org/10.1016/0264-410X(92)90324-D
Holmgren J, Svennerholm AM, Jertborn M, Clemens J, Sack DA, Salenstedt R et al. An oral B subunit: whole cell vaccine against cholera. Vaccine. 1992;10(13):911-914. https://doi.org/10.1016/0264-410X(92)90324-D
Holmgren, J. ; Svennerholm, A. M. ; Jertborn, M. ; Clemens, J. ; Sack, D. A. ; Salenstedt, R. ; Wigzell, H. / An oral B subunit : whole cell vaccine against cholera. In: Vaccine. 1992 ; Vol. 10, No. 13. pp. 911-914.
@article{e26ad7d48fbe4f2d9ba34e4b53023831,
title = "An oral B subunit: whole cell vaccine against cholera",
abstract = "During the last decade there has been a rapid progress in the development of new, much improved vaccines against cholera. These vaccines, which are given orally to stimulate the gut mucosal immune system, are based on either a combination of purified cholera toxin B (binding) subunit and killed cholera vibrios of Inaba and Ogawa serotypes and El Tor and classical biotypes (B subunit-whole cell vaccine, B-WC) or on a live attenuated mutant strain of Vibrio cholerae producing the B subunit (CVD 103-HgR). The safety of the oral B-WC cholera vaccine and the immunogenicity and protective efficacy of this vaccine against both cholera and diarrhoea caused by enterotoxigenic Escherichia coli have been extensively documented, e.g. in a large randomized, placebo-controlled field trial in 90 000 persons living in a cholera endemic area. The potential for inexpensive large-scale manufacturing of the B-WC vaccine has recently been much facilitated by the introduction of recombinant DNA technology for production of the B subunit component. This now gives promise that this vaccine could become a useful, cost-effective tool in future strategies to control cholera both in endemic situations and in relation to acute epidemic outbreaks.",
keywords = "B subunit-whole cell vaccine, Cholera, field trials, oral",
author = "J. Holmgren and Svennerholm, {A. M.} and M. Jertborn and J. Clemens and Sack, {D. A.} and R. Salenstedt and H. Wigzell",
year = "1992",
doi = "10.1016/0264-410X(92)90324-D",
language = "English (US)",
volume = "10",
pages = "911--914",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "13",

}

TY - JOUR

T1 - An oral B subunit

T2 - whole cell vaccine against cholera

AU - Holmgren, J.

AU - Svennerholm, A. M.

AU - Jertborn, M.

AU - Clemens, J.

AU - Sack, D. A.

AU - Salenstedt, R.

AU - Wigzell, H.

PY - 1992

Y1 - 1992

N2 - During the last decade there has been a rapid progress in the development of new, much improved vaccines against cholera. These vaccines, which are given orally to stimulate the gut mucosal immune system, are based on either a combination of purified cholera toxin B (binding) subunit and killed cholera vibrios of Inaba and Ogawa serotypes and El Tor and classical biotypes (B subunit-whole cell vaccine, B-WC) or on a live attenuated mutant strain of Vibrio cholerae producing the B subunit (CVD 103-HgR). The safety of the oral B-WC cholera vaccine and the immunogenicity and protective efficacy of this vaccine against both cholera and diarrhoea caused by enterotoxigenic Escherichia coli have been extensively documented, e.g. in a large randomized, placebo-controlled field trial in 90 000 persons living in a cholera endemic area. The potential for inexpensive large-scale manufacturing of the B-WC vaccine has recently been much facilitated by the introduction of recombinant DNA technology for production of the B subunit component. This now gives promise that this vaccine could become a useful, cost-effective tool in future strategies to control cholera both in endemic situations and in relation to acute epidemic outbreaks.

AB - During the last decade there has been a rapid progress in the development of new, much improved vaccines against cholera. These vaccines, which are given orally to stimulate the gut mucosal immune system, are based on either a combination of purified cholera toxin B (binding) subunit and killed cholera vibrios of Inaba and Ogawa serotypes and El Tor and classical biotypes (B subunit-whole cell vaccine, B-WC) or on a live attenuated mutant strain of Vibrio cholerae producing the B subunit (CVD 103-HgR). The safety of the oral B-WC cholera vaccine and the immunogenicity and protective efficacy of this vaccine against both cholera and diarrhoea caused by enterotoxigenic Escherichia coli have been extensively documented, e.g. in a large randomized, placebo-controlled field trial in 90 000 persons living in a cholera endemic area. The potential for inexpensive large-scale manufacturing of the B-WC vaccine has recently been much facilitated by the introduction of recombinant DNA technology for production of the B subunit component. This now gives promise that this vaccine could become a useful, cost-effective tool in future strategies to control cholera both in endemic situations and in relation to acute epidemic outbreaks.

KW - B subunit-whole cell vaccine

KW - Cholera

KW - field trials

KW - oral

UR - http://www.scopus.com/inward/record.url?scp=0026795591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026795591&partnerID=8YFLogxK

U2 - 10.1016/0264-410X(92)90324-D

DO - 10.1016/0264-410X(92)90324-D

M3 - Article

C2 - 1471411

AN - SCOPUS:0026795591

VL - 10

SP - 911

EP - 914

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 13

ER -